Home › NDC Lookup › RxCUI directory › RxCUI 1939335

Sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG Oral Tablet [Vosevi] — RxCUI 1939335

RxNorm drug concept · Semantic branded drug
RxCUI 1939335 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1939335
Official nameSofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG Oral Tablet [Vosevi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVosevi 400/100/100 Oral Tablet; Vosevi 400 MG / 100 MG / 100 MG Oral Tablet; Vosevi 400/100/100 (sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG) Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)1,014 prescriptions · 18 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Sofosbuvir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Sovaldi works by blocking a specific enzyme the hepatitis C virus needs to copy itself. When used correctly as part of a combination treatment, many people do clear the virus compl...
  • What exactly does Sovaldi do — is it a cure for hepatitis C?
  • You can take Sovaldi with or without food — it doesn't matter. Studies showed that even a high-fat meal doesn't significantly change how much medicine gets into your system. Just t...
  • Can I take Sovaldi with food, or does it need to be on an empty stomach?
📖 Read our full Sofosbuvir guide →

🕸️ Concept Web — How Sofosbuvir 400 MG / velpatasvir 100 MG / voxilap... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG Oral Tablet [Vosevi] RxCUI 1939335

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 4

    The active substance itself — no strength, form, or brand attached yet.

    • Sofosbuvir 1484911
    • Velpatasvir 1799206
    • Voxilaprevir 1939323
    • Sofosbuvir / velpatasvir / voxilaprevir 1939328
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vosevi 1939330
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Sofosbuvir / velpatasvir / voxilaprevir Oral Tablet 1939327
    • Sofosbuvir / velpatasvir / voxilaprevir Oral Product 1939325
    • Sofosbuvir / velpatasvir / voxilaprevir Pill 1939326
    • Sofosbuvir / velpatasvir / voxilaprevir Oral Tablet [Vosevi] 1939332
    • Vosevi Oral Product 1939333
    • Vosevi Pill 1939334
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 5

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG Oral Tablet SCD · 1939329
  • Sofosbuvir 400 MG SCDC · 1484912
  • Velpatasvir 100 MG SCDC · 1799207
  • Voxilaprevir 100 MG SCDC · 1939324
  • Sofosbuvir / velpatasvir / voxilaprevir Oral Tablet SCDF · 1939327
  • Sofosbuvir / velpatasvir / voxilaprevir Oral Product SCDG · 1939325
  • Sofosbuvir / velpatasvir / voxilaprevir Pill SCDG · 1939326

Brand-Name Concepts

  • Sofosbuvir 400 MG / velpatasvir 100 MG / voxilaprevir 100 MG [Vosevi] SBDC · 1939331
  • Sofosbuvir / velpatasvir / voxilaprevir Oral Tablet [Vosevi] SBDF · 1939332
  • Vosevi Oral Product SBDG · 1939333
  • Vosevi Pill SBDG · 1939334
  • Vosevi BN · 1939330

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1939335 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
61958-2401-01 28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-2401-1) Vosevi Gilead Sciences, Inc. 2017-07-18
Observed labelers: Gilead Sciences, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.